Active immunisation against human tick-borne diseases

Expert Opinion on Biological Therapy

Volumn 2, Issue 2, 2002, Pages 187-195

  Bratu, Simona ^a   Lutwick, Larry I ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Immunisations; Lyme disease; Ticks; Vaccines

Indexed keywords

ANTIGEN; BM86; ENCEPHUR; FSME IMMUNE; GAVAC; LYME DISEASE VACCINE; Q FEVER VACCINE; Q VAX; RICKETTSIA VACCINE; ROCKY MOUNTAIN SPOTTED FEVER VACCINE; TICK ANTIGEN; TICK BORNE ENCEPHALITIS VACCINE; TICK PARALYSIS VACCINE; TICKGUARD; TULAREMIA VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ACTIVE IMMUNIZATION; BOOPHILUS MICROPLUS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; INJECTION PAIN; KYASANUR FOREST DISEASE VIRUS; LYME DISEASE; MYALGIA; NAUSEA AND VOMITING; NONHUMAN; Q FEVER; RASH; REVIEW; ROCKY MOUNTAIN SPOTTED FEVER; TICK BITE; TICK BORNE DISEASE; TICK BORNE ENCEPHALITIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TULAREMIA; VECTOR CONTROL; VIRUS INFECTION; ANIMAL; IMMUNOLOGY; TICK; VACCINATION;

ACARI; ARTHROPODA; BOOPHILUS MICROPLUS; KYASANUR FOREST DISEASE VIRUS; RICKETTSIA;

ANIMALS; ENCEPHALITIS, TICK-BORNE; HUMANS; KYASANUR FOREST DISEASE; LYME DISEASE; ROCKY MOUNTAIN SPOTTED FEVER; TICK-BORNE DISEASES; TICKS; TULAREMIA; VACCINATION;

EID: 0035989766     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.2.187     Document Type: Review

References (61)

1. A short history of vaccination
2. Lyme disease - United States, 1987 and 1988
3. Emerging zoonoses
4. Recommendations for the use of Lyme disease vaccine
5. Lyme disease: A growing threat to urban populations
6. The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study
7. Passive immunizing activity of sera from mice infected with Borrelia burgdorferi
8. Monoclonal antibodies specific for the outer surface protein OspA of Borrelia burgdorferi prevent Lyme borreliosis in severe combine immunodeficicncy (SCID) mice
9. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine
10. Prospects for a vaccine to prevent Lyme disease in humans
11. Evaluation of the safety, reactogenicity and immmogenicity of three recombinant outer surface proteins (OspA) Lyme vaccines in healthy adults
12. Immunization against Lyme disease - An important first step
13. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant
14. A vaccine consisting of recombinant outer-surface protein A to prevent Lyme disease
15. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months
16. Reactogenicity and immmogenicity of a Lyme disease vaccine in children 2-5 years old
17. Immunoglobulin (Ig G) antibody response to Osp A and Osp B correlates with severe and prolonged lyme arthritis and the IgG response to P35-correlates with mild and brief arthritis
18. An OspC-specific monoclonal antibody passively protects mice from tick-transmitted infection by Borrella burgdorferi B31
19. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but not for resolution of Lyme disease
20. Evidence for vaccine synergy between Borrelia burgdorferi decorin binding protein A and outer surface protein A in the mouse model of Lyme borreliosis
21. Decorin-binding protein A (DbpA) of Borrelia burgdorferi is not protective when immunized mice are challenged via tick infestation and correlates with the lack of DbpA expression by B. burgdorferi in ticks
22. Protection against tick borne encephalitis virus isolated in Japan by active and passive immunisation
23. Tick-borne encephalitis vaccine
24. Tick-borne encephalitis
25. Vaccination against tick-borne encephalitis, a flavivirus, prevents disease but not infection, although viremia is undetectable
26. Antigenic and immunogenic properties of defined physical forms of rick-borne encephalitis virus structural proteins
27. A randomised Phase II study of a new tick-borne encephalitis vaccine using three different doses and two immunization regimens
28. An accelerated schedule for tick-borne encephalitis vaccine. The American military experience in Bosnia
29. Neurological complications after the simultaneous immunization against tick-borne encephalitis and tetanus
30. Towards a new generation of flavivirus vaccines
31. Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis
32. Tick-borne diseases in the United States
33. Rocky Mountain spotted fever vaccine in an animal model
34. Reactogenicity, immunogenicity, and efficacy of a chick embryo cell-derived vaccine for Rocky Mountain spotted fever
35. Cell-mediated immune responses of adults to vaccination, challenge with Rickettsia ricketsii, or both
36. Extraction of protective components of Rickettsia rickettsii with noctyl-beta-D-glucopyranoside
37. Protection of guinea-pigs from experimental Rocky Mountain spotted fever by immunization with baculovirus-expressed Rickettsia rickettsii rOmp A protein
38. Tularemia as a biological weapon. Medical and public health management
39. Soviet viable Pasteurella tularensis vaccine. A review of selected articles
40. Immunization against potential biological warfare agents
41. Nature of protective immunity to Francisella tularensis
42. Laboratory-acquired tularemia in vaccinated individuals: A report of 62 cases
43. Immunization against tularemia: Analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratory-acquired tularemia
44. Prophylactic effectiveness of live and killed tularemia vaccines. I. Products of vaccine and evaluation in the white mouse and guinea pig
45. A capsule deficient mutant of Francisella tularensis LVS exhibits enhanced sensitivity to killing by polymorphonuclear leukocyres
46. Cell-mediated and humoral immune response induced by scarification vaccination of human volunteers with a new lot of the live vaccine strain of Francisella tularensis
47. Ticks and tickborne bacterial diseases in humans. An emerging infectious threat
48. Vaccine prophylaxis of abbatoir - Associated Q fever: Eight years experience in Australian abattoirs
49. Field evaluation of formalin inactivated Kyasanur forest disease virus tissue culture vaccine in three districts of Karnataka state
50. Tick bite paralysis
51. Tick paralysis: Development of a vaccine
52. Acquired immunity to ticks
53. An increase in death rate of Anopheles stephensi fed on rabbits immunized with mosquito antigen
54. Observations on Glossina morsitans morsitans maintained on rabbits immunized with crude tsetse midgut proteases
55. Vaccines against arthropods
56. Arthropod vaccines
57. Vaccination against ticks (Boophilus spp.): The experience with the Bm86-based vaccine Gavac
58. Immunoglobulin-binding proteins in ticks: New target for vaccine development against a blood-feeding parasite
59. Control of ticks resistant to immunization with Bm86 in cattle vaccinated with the recombinant antigen Bm95 isolated from the cattle tick, Boophilus microplus
60. Evaluation of Tickguard (PLUS), a novel vaccine against Boophilus microplus, in lactating Holstein-Friesian cows
61. Resistance to tick-borne Francisella tularensis by tick-sensitized rabbits: Allergic klendusity